Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Medikamentöse Intervention bei Herzrhythmusstörungen

  • Chapter
Interventionen am Herzen

  • 32 Accesses

Zusammenfassung

Medikamentöse Interventionen bei Herzrhythmusstörungen sollen im folgenden unter 2 Aspekten besprochen werden:

  • Akutinterventionen bei in der Regel tachykarden, hämodynamisch bedeutsamen Herzrhythmusstörungen. Bei den meisten dieser Arrhythmien ist die medikamentöse Intervention Therapie der ersten Wahl und absolut unbestritten;

  • Chronische Interventionen zur dauerhaften Unterdrückung von Ektopien oder zur permanenten prophylaktischen Beeinflussung potentieller Reentrykreise, um das Auftreten bedrohlicher anhaltender Tachykardien zu verhindern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Akhtar M, Shenasa M, Tchou PJ, Jazayeri M (1987) Role of electrophysiologic studies in supraventricular tachycardia. In: Brugada P, Wellens HJJ (eds) Cardiac arrhythmias: where to go from here? Mount Kisco, New York, Futura Publishing Co pp 233

    Google Scholar 

  2. Amlie JP, Storstein L (1980) Effects of autonomic blockade on the inotropic and electrophysiologic response to digitoxin in the intact dog. J Cardiovasc Pharmacol 2: 55

    PubMed  CAS  Google Scholar 

  3. Andresen D, Tietze U, von Leitner ER, Lehmann HU, Thormann I, Wessel HJ, Schröder R (1980) Spontanvariabilität tachykarder Rhythmusstörungen, Z Kardiol 59: 214

    Google Scholar 

  4. Bastian BC, McFarland PW, McLauchlan JH et al. (1980) A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J 100: 1017

    PubMed  CAS  Google Scholar 

  5. Bayes de Luna A, Coumel P, Leclercq JF (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151

    PubMed  CAS  Google Scholar 

  6. Belhassen B, Horowitz LN (1984) Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol 54: 1131

    PubMed  CAS  Google Scholar 

  7. Belhassen B, Viskin S (1993) What is the drug of choice for the acute termination of paroxysmal supraventricular tachycardia: verapamil, adenosine, triphosphate, or adenosine? PACE 16: 1735

    PubMed  CAS  Google Scholar 

  8. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, the Multicenter Post-Infarction Research Group (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69: 250

    PubMed  Google Scholar 

  9. Bigger JR, Jaffe C (1971) The effect of bretylium tosylate on the electrophysiological properties of ventricular muscle and Purkinje fibers. Am J Cardiol 27: 82

    PubMed  CAS  Google Scholar 

  10. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58: 496

    PubMed  CAS  Google Scholar 

  11. Brugada P, Brugada J, Mont L, Smeets J, Andries E (1991) A new approach to the differential diagnosis of a regular tachycardia. Circulation 83:1649

    PubMed  CAS  Google Scholar 

  12. Burkart F, Pfisterer M, Kiowski W, Burckhardt P, Follath F (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol 16: 1711

    PubMed  CAS  Google Scholar 

  13. Calkins H, Sousa J, El-Atassi R, et al. (1991) Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachyardias during a single electrophysiologic test. Engl J Med 324: 1612

    CAS  Google Scholar 

  14. Camm AJ, Garratt CJ (1991) Adenosine and supraventricular tachycardia. N Engl J Med 325: 1621

    PubMed  CAS  Google Scholar 

  15. Campbell TJ (1990) Proarrhythmic actions of antiarrhythmic drugs: a review. Aust NZ J Med 20: 275

    CAS  Google Scholar 

  16. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227

    Google Scholar 

  17. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227

    Google Scholar 

  18. CAST investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406

    Google Scholar 

  19. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M et al. (1992) Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 20: 1056

    PubMed  CAS  Google Scholar 

  20. Chamberlain DA, Jewitt DE, Julian DG, Campbell RW, Boyle DM, Shanks RG (1980) Oral mexiletine in high-risk patients after myocardial infarction. Lancet II: 1324

    Google Scholar 

  21. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P (1992) Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 70: 44A

    PubMed  CAS  Google Scholar 

  22. Collaborative Group (1971) Phenytoin after recovery from myocardial infarction: Controlled trial in 568 patients. Lancet 2: 1055

    Google Scholar 

  23. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm. Circulation 82: 1106

    PubMed  CAS  Google Scholar 

  24. Coumel P, Leclercq JF, Attuel P, Lavallee JP, Flammang D (1979) Autonomic influences in the genesis of atrial arrhythmias: Atrial flutter and fibrillation of vagal origin. In: Narula OS (ed) Cardiac arrhythmic Electrophysiology, diagnosis and management. William & Wilkins, Baltimore London, p 243

    Google Scholar 

  25. Coumel P, Leclercq JF, Attuel P (1982) Paroxysmal atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. AB Hässle, Mölndal, p 158

    Google Scholar 

  26. Danilo P Jr. (1979) Mexiletine. Am Heart J 97: 399

    PubMed  Google Scholar 

  27. Davison R, Parker M, Atkinson AJ (1982) Excessive serum lidocaine levels during maintainance infusions: mechanisms and prevention. Am Heart J 104: 203

    PubMed  CAS  Google Scholar 

  28. De Paola AAV, Horowitz LN, Morganroth J, Senior S, Spielman SR, Greenspan AM, Kay HR (1987) Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol 9:163

    PubMed  Google Scholar 

  29. Dias VC, Weir SJ, Ellenbogen KA (1992) Pharmacokinetics and pharmocodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Circulation 86: 1421

    PubMed  CAS  Google Scholar 

  30. DiMarco JP, Sellers TD, Lerman BB, Greenberg ML, Berne RM, Belardinelli L (1985) Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 6: 417

    PubMed  CAS  Google Scholar 

  31. Echt DS, Liebson PR, Mitchell LB et al. (1991) Mortality and morbity in patients receiving encaiinide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 324: 781

    PubMed  CAS  Google Scholar 

  32. Edvardsson N, Olsson SB (1982) Outpatient electroconversion of chronic atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. AB Hässle, Mölndal, p 242

    Google Scholar 

  33. Eichelbaum M, Spannbrucker N, Dengler AJ (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics. Europ J Clin Pharmacol 16:189

    CAS  Google Scholar 

  34. Eldar M, Griffin JC, van Hare GF, Witherell C, Bhandari A, Benditt D, Scheinmann MM (1992) Combined use of betaadrenergic agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 20: 830

    PubMed  CAS  Google Scholar 

  35. Elfner R, Kollmeier W, Lentz A et al. (1986) Dosis-Wirkungs-Beziehung von N-Prajmaliumbitartrat unter Plasmaspiegelkontrolle. Z Kardiol 75: 402

    PubMed  CAS  Google Scholar 

  36. Escourbet B, Coumel P, Poirier JM et al. (1985) Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. Am J Cardiol 55: 696

    Google Scholar 

  37. Ettinger PO, Wu CF, De la Cruz C, Weisse AB, Ahmed SS, Regan TJ (1978) Arrhythmias and the „holiday heart“: alcohol-associated cardiac rhythm disorders. Am Heart J 95: 555

    PubMed  CAS  Google Scholar 

  38. Fleckenstein A (1970) Die Zügelung des Myocardstoffwechsels durch Verapamil: Angriffspunkte und Anwendungsmöglichkeiten. Arzneimittelforsch 20: 131

    Google Scholar 

  39. Fleckenstein A (1975) Fundamentale Herz- und Gefäßwirkungen Ca-antagonistischer Koronartherapeutika. Med Klin 70: 1665

    PubMed  CAS  Google Scholar 

  40. Fogoros RN (1993) The effect of the implantable cardioverter defibrillator on sudden death and on total survival. PACE 16: 506

    PubMed  CAS  Google Scholar 

  41. Gouaux JL, Ashman B (1947) Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia. Am Heart J 34: 366

    PubMed  CAS  Google Scholar 

  42. Greene HL (1989) The Efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. Progress in Cardiovascular Diseases XXXI, 5: 319

    Google Scholar 

  43. Greene HL, Graham EL, Werner JA et al. (1983) Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 2: 1114

    PubMed  CAS  Google Scholar 

  44. Guerot C, Coste A, Valere PE, Tricot R (1973) L’epreuve a l’Ajmaline dans le diagnostic du bloc auriculoventriculaire paroxystique. Arch Mal Coeur 66: 1241

    PubMed  CAS  Google Scholar 

  45. Haverkamp W, Hördt M, Chen X, Hindricks G, Willems S, Kottkamp H, Rotman B, Brunn J, Borggrefe M, Breithardt G (1993) Torsades de pointes. Z Kardiol 82: 763

    PubMed  CAS  Google Scholar 

  46. Hohnloser SH, Zabel M, van de Loo A, Klingenheben T, Just H (1992) Efficacy and safety of Sotalol in patients with complex ventricular arrhythmias. Int J Cardiol 37: 283

    PubMed  CAS  Google Scholar 

  47. Hohnloser SH, van de Loo A, Baedecker F, Hablawetz E, Just H (1994) Effektivität und Sicherheit von Sotalol versus Chinidin zur Konversionstherapie von persistierendem Vorhofflimmern: Ein prospektiver randomisierter Vergleich. Z Kardiol 83 (Suppl 1): 13

    Google Scholar 

  48. Homburger H, Antoni H (1974) Elektrophysiologische Effekte von N-Propyl-Ajmalinium-hydrogentartrat (NPAB) am isolierten Säugetiermyokard. In: Antoni H, Effert S (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart New York, S 180–195

    Google Scholar 

  49. Hony RM, Ritchie WT, Thomson WAR (1930) The action of adenosine upon the human heart. Q J Med 23: 485

    Google Scholar 

  50. Hood MA, Smith WM (1992) Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-cross-over trial. Am Heart J 123:1543

    PubMed  CAS  Google Scholar 

  51. Hugenholtz PG, Hagemeijer F, Lubsen J, Glazer B, van Durme JP, Bogaert MG (1978) One year follow-up in patients with persistent ventricular dysrhythmias after myocardial infarction treated with aprindine or placebo. Excerpta Med 572:8

    Google Scholar 

  52. Impact Research Group (1984) International mexilltine and placebo antiarrhythmic coronary trial, a report on arrhythmia and other findings. J Am Coll Cardiol 4: 1148

    Google Scholar 

  53. Jackman, WM, Beckman KJ, McClelland JH et al. (1992) Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 327: 31

    Google Scholar 

  54. Jähnchen E, Trenk D (1983) Pharmakokinetische Prinzipien und spezielle Pharmakokinetik der Antiarrhythmika. In: Lüderitz B (Hrsg) Herzrhythmusstörungen. Handbuch der Inneren Medizin, Bd IX/1. Springer, Berlin Heidelberg New York Tokyo, S 167

    Google Scholar 

  55. Jenzer HR, Hagemeijer F (1976) Quinidine syncope: torsades de pointes with low quinidine plasma concentrations. Europ J Cardiol 4: 447

    CAS  Google Scholar 

  56. Jerwell A, Lange-Nielsen F (1957) Congenital deaf-mutism, functional heart disease with prolongation auf the Q-T interval and sudden death. Am Heart J 54: 59

    Google Scholar 

  57. Jezer A, Oppenheimer BS, Schwartz SP (1933) The effect of adenosine cardiac irregularities in man. Am Heart J 9: 252

    CAS  Google Scholar 

  58. Kalusche D, Stockinger J, Betz P, Roskamm H (1994) Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhofflimmern — Konversion und 12-Monats-Follow-up -Ein randomisierter Vergleich. Z Kardiol 83 (Suppl 5): 109

    PubMed  Google Scholar 

  59. Kalusche D, Behroz A, Betz P, Roskamm H (1991) Aussagekraft diastolischer Flußmessungen mittels PW-Doppler nach Konversion von Vorhofflimmern (AA) im Hinblick auf die Erhaltung des Sinusrhythmus (SR). Z Kardiol 80 (Suppl 3): 43

    Google Scholar 

  60. Kalusche D (im Druck) Antikoagulation und Aggregationshemmer bei Herzerkrankungen (3). In: Roskam H, Reindell H (Hrsg) Herzkrankheiten, 4. Aufl. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  61. Karagueuzian HS, Singh BN, Mandel WJ (1987) Antiarrhythmic drugs: mode of action, pharmacokinetic properties, and clinical application. In: Mandel WJ (ed) Cardiac arrhythmias. Lippincott JB, Philadelphia London, p 697

    Google Scholar 

  62. Kay GN, Epstein AE, Dailey SM, Plumb VJ (1993) Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovas Electrophysiol 4: 371

    CAS  Google Scholar 

  63. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppart M (1991) Linkage of cardiac arrhythmia, the long QT syndrome, and Harvey ras-1 gene. Science 252: 704

    PubMed  CAS  Google Scholar 

  64. Kindwall KE, Brown J, Josephson ME (1988) Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol 61:1279

    PubMed  CAS  Google Scholar 

  65. Klein, LS, Miles WM, Hackett FK, Zipes DP (1992) Catheter ablation of ventricular tachycardia using radiofrequency techniques in patients without structural heart disease. Herz 17: 179

    PubMed  CAS  Google Scholar 

  66. Leclercq JF, Chouty F, Denjoy I, Coumel P, Slama R (1992) Flecainide in quinidine-resistant atrial fibrillation. Am J Cardiol 70: 6

    Google Scholar 

  67. Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P (1994) Short-coupled variant of torsade de pointes. Circulation 89: 206

    PubMed  CAS  Google Scholar 

  68. Lindsay BD, Chung MK, Gamache MC, Luke RA, Schechtman KB, Osborn JL, Cain ME (1993) Therapeutic end points for the treatment of atrioventricular node reentrant tachycardia by catheter-guided radiofrequency current. J Am Coll Cardiol 22: 733

    PubMed  CAS  Google Scholar 

  69. Mackenzie J (1914) Diseases of the heart, 3rd edn. Oxford Medical Publications, London, pp 211

    Google Scholar 

  70. Manz M, Mletzko R, Jung W, Lüderitz B (1992) Electrophysiologic and hemodynamic effects of lidocaine and ajmahne in the management of sustained ventricular tachycardia. Europ Heart J 13:1123

    CAS  Google Scholar 

  71. Manz M, Wagner WL, Lüderitz B (1988) Combination of mexiletine and Sotalol in complex ventricular arrhythmias. N Trends Arrhyt 6 (Suppl): 35

    Google Scholar 

  72. Manz M, Lüderitz B (1988) Vergleichende Untersuchung von Ajmalin und Lidocain bei ventrikulären Tachyarrhythmien. In: Lüderitz B, Antoni H (Hrsg) Perspektiven der Arrhythmiebehandlung. Springer, Berlin Heidelberg New York Tokyo, S3

    Google Scholar 

  73. Marcus FI (1983) Drug interactions with amiodarone. Am Heart J 106: 924

    PubMed  CAS  Google Scholar 

  74. Mason JW (1993) A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329: 445

    PubMed  CAS  Google Scholar 

  75. Mclntosh-Yellin NL, Drew BJ, Scheinman MM (1993) Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia. J Am Coll Cardiol 22: 741

    Google Scholar 

  76. Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN (1988) Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 319 5: 257

    PubMed  CAS  Google Scholar 

  77. Morady F, Baerman JM, DiCarlo LA, DeBuitleir M, Krol RB, Wahr DW (1985) A prevalent misconception regarding wide-complex tachycardias. JAMA 254: 2790

    PubMed  CAS  Google Scholar 

  78. Morganroth J, Michelson EL, Horowitz LN, Josephson ME, Pearlmann AS, Dunkman B (1978) Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 58: 408

    PubMed  CAS  Google Scholar 

  79. Moss AJ, Schwartz PJ (1982) Delayed repolarization (QTor QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 51: 85

    PubMed  CAS  Google Scholar 

  80. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ (1991) The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 84:1136

    PubMed  CAS  Google Scholar 

  81. Nademanee K, Piwonka RW, Singh BN, Hershman JM (1989) Amiodarone and thyroid function. Progr Cardiovasc Dis XXXI 6: 427

    Google Scholar 

  82. Neuss H, Horn HG, Mitrovic V, Schlepper M (1979) Die Wirkung des Calcium-Antagonisten D 600 bei Knotentachykardien. Z Kardiol 68: 643

    Google Scholar 

  83. Nisam S, Mower M, Moser S (1991) ICD clinical update: first decade, initial 10.000 patients. PACE 14: 255

    PubMed  CAS  Google Scholar 

  84. Nguyen PT, Scheinman MM, Seger J (1986) Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 74: 340

    PubMed  CAS  Google Scholar 

  85. Pantridge JF (1974) Prehospital coronary care. Br J Heart 36: 233

    CAS  Google Scholar 

  86. Pearl WR (1982) Massive lidocaine overdose. Am Heart J 103: 1083

    PubMed  CAS  Google Scholar 

  87. Peters T, Ross D, Duffield A, Luxton M, Harper R, Hurt D, Sloman G (1978) Effect on survival after myocardial infarction of longterm treatment with phenytoine. Br Heart J 40: 1356

    Google Scholar 

  88. Platia EV, Estes NAM, Heine DL, Griffith L, Garan H, Ruskin JN, Reid PR (1985) Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 55: 956

    PubMed  CAS  Google Scholar 

  89. Podrid PJ, Schoeneberger A, Lown B (1980) Congestive heart failure caused by oral disopyramide. N Engl J Med 302: 614

    PubMed  CAS  Google Scholar 

  90. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB (1989) The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapie: a dangerous imbalance in the risk-benefit ratio. Am Heart J 118: 433

    PubMed  CAS  Google Scholar 

  91. Probst P (1975) Die Indikation zur prophylaktischen Schrittmacherimplantation bei hochgradigen atrioventrikulären Überleitungsstörungen. Z Kardiol 64: 926

    PubMed  CAS  Google Scholar 

  92. Rankin AC, Oldroyd KG, Chong E, Rae AP, Cobbe SM (1989) Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J 62:195

    PubMed  CAS  Google Scholar 

  93. Ricci DR, Orlick AE, Reitz BA, Mason JW, Stinson EB, Harrison DC (1978) Depressant effect of digoxin on atrioventricular conduction in man. Circulation 57: 898

    PubMed  CAS  Google Scholar 

  94. Rizzon P, de Biase M, Favale S, Visani L (1987) Class Ib agents lidocaine mexiletine, tocainide, phenytione. Europ Heart J8 (Suppl A): 21

    Google Scholar 

  95. Roden DM, Woosley RL, Primm RK (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111: 1088

    PubMed  CAS  Google Scholar 

  96. Romano C, Gemme G, Pongiglione R (1963) Aritmie cardiache rare dell’eta’ pediatrica. La Clinica Pediatrica 45:656

    PubMed  CAS  Google Scholar 

  97. Ryden L, Amman K, Conradson TB, Hofvendahl S, Mortensen O, Smedgard P (1980) Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100:10

    Google Scholar 

  98. Sami M, Kraemer H, Harrison DC, Houston N, Shimasaki C, de Busk RF (1980) A new method for evaluating antiarrhythmic drug efficacy. Circulation 62: 1172

    PubMed  CAS  Google Scholar 

  99. Schaumlöffel E (1974) Pharmakokinetische Studien mit radioaktiv markiertem N-n-Propyl-Ajmalinium-Hydrogentartrat an Ratte und Mensch. In: Antoni H, Effert S (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart NewYork, S209

    Google Scholar 

  100. Schlepper M (1987) Propafenone, a review of its profile. Europ Heart J 8 (Suppl A): 27

    Google Scholar 

  101. Schmidt G, Barthel P, Ulm K, Herb H, Kreuzberg L, Goedel-Meinen L, Baedeker W, Blömer H (1991) Antiarrhythmische Therapiekontrolle mittels Holter-Monitoring. In: Schmidt G (Hrsg) Medikamentöse Behandlung des Postinfarktpatienten nach CAST. Steinkopff, Darmstadt, S 55

    Google Scholar 

  102. Schmidt G, Ulm K, Goedel-Meinen L et al. (1986) Kriterien zur Sicherung antiarrhythmischer Effekte im Langzeit-EKG unter Berücksichtigung des Kontrollintervalls. Z Kardiol 75 (Suppl 4): 62

    Google Scholar 

  103. Schwartz PJ, Periti M, Malliani A (1975) The long QT-syndrome. Am Heart J 89: 378

    PubMed  CAS  Google Scholar 

  104. Schwartz JB, Keefe EL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elminiation kinetics during chronic oral administration. Am Heart J 104:198

    PubMed  CAS  Google Scholar 

  105. Selzer A, Wray HW (1964) Quinidine syncope. Paroxysmal ventricular fibrillation during treatment of chronic atrial arrhythmias. Circulation 30: 17

    PubMed  CAS  Google Scholar 

  106. Sethi KK, Manoharan S, Mohan JC, Gupta MP (1986) Verapamil in idiopathic ventricular tachycardia of right bundle branch block morphology: Oberservations during electrophysiologic and exercise testing. PACE 9: 8

    PubMed  CAS  Google Scholar 

  107. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 755

    Google Scholar 

  108. Singh BN, Vaughan-Williams EM (1970) A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3676. Brit J Pharmacol 39: 675

    CAS  Google Scholar 

  109. Singh BN, Vaughan Williams EM (1970) The effect of amiodarone, a new anti-anginal drug on cardiac muscle. Brit J Pharmacol 39: 657

    CAS  Google Scholar 

  110. Slater W, Lampert S, Podrid PJ, Lown B (1988) Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 61: 349

    PubMed  CAS  Google Scholar 

  111. Smith MS, Verghese CP, Shand DG, Pritchett ELC (1983) Phamacokinetic and pharmocodynamic effects of diltiazem. Am J Cardiol 51: 1369

    PubMed  CAS  Google Scholar 

  112. Stanton MS, Prystowsky EN, Fineberg NS, Miles WN, Zipes DP, Heger JJ (1987) Incidence of ventricular tachycardia and ventricular fibrillation as proarrhythmic effects during treatment of ventricular arrhythmia. J Am Coll Cardiol 9: 245A

    Google Scholar 

  113. Steinbeck G, Bach P, Haberl R (1986) Electrophysiologic and antiarrhythmic efficacy of oral Sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol 8: 949

    PubMed  CAS  Google Scholar 

  114. Steinbeck G, Dolwina R, Bach P (1986) Glykoside für paroxysmales Vorhofflimmern? Z Kardiol 75 (Suppl I): 24

    Google Scholar 

  115. Stewart RB, Bardy GH, Greene HL (1986) Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 104: 766

    PubMed  CAS  Google Scholar 

  116. Storey GC, Holt DW (1982) High performance liquid chromatographic measurements of amiodarone and desethyl amiodarone in plasma or serum at concentrations obtained following a single 400 mg dose. J Chromatograph 245: 377

    CAS  Google Scholar 

  117. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology (1990) CAST and beyond implications of the cardiac arrhythmia suppression trial. Eur Heart J 11:194

    Google Scholar 

  118. Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD (1987) Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 10: 633

    PubMed  CAS  Google Scholar 

  119. Thormann J, Schlepper M (1983) Hämodynamische Auswirkungen kardialer Arrhythmien. In: Lüderitz B (Hrsg) Herzrhythmusstörungen. Handbuch der Inneren Medizin, Bd IX/1. Springer, Berlin Heidelberg New York Tokyo, S 355

    Google Scholar 

  120. Trappe HJ, Brugada P, Talajic M, Lezaun R, Wellens HJJ (1989) Herzrhythmusstörungen: Prognose und Verlauf von Patienten mit Kammertachykardien oder Kammerflimmern ohne koronare Herzkrankheit. Z Kardiol 78:500

    PubMed  CAS  Google Scholar 

  121. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, Stern S (1988) Treatment of torsades de pointes with magnesium sulfate. Circulation 77: 392

    PubMed  CAS  Google Scholar 

  122. Vaughan Williams EM (1991) Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol 31: 123

    PubMed  CAS  Google Scholar 

  123. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886

    PubMed  CAS  Google Scholar 

  124. Vrobel TR, Miller PE, Mostow ND, Rakita L (1989) A general overview of amiodarone toxicity: its prevention, detection, and management. Progr Cardiovasc Dis XXXI 6:393

    Google Scholar 

  125. Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H (1986) Kumulation von Metoprolol im Plasma unter der Therapie mit Propafenon. Z Kardiol 75 (Suppl I): 25

    Google Scholar 

  126. Ward EC (1964) A new familial cardiac syndrom in children. J Irish Med Ass 54: 103

    CAS  Google Scholar 

  127. Wegscheider K, Andresen D, von Leitner ER, Schröder R (1982) Neue Methode zur Erfassung der Spontanvariabilität einfacher und komplexer Rhythmusstörungen in Abhängigkeit von der Häufigkeit ihres Auftretens. Z Kardiol 71: 179

    Google Scholar 

  128. Weidner A, Engels J (1979) Nebenwirkungen rhythmisierender Substanzen. In: Antoni H, Bender F, Gerlach E, Schlepper M (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart New York, S 387

    Google Scholar 

  129. Weinberg BA, Miles Wm, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C, Zipes DP (1993) Five-year follow-up 589 patients treated with amiodarone. Am Heart J 125:109

    PubMed  CAS  Google Scholar 

  130. Wellens HJJ, Bar FW, Lie KI (1978) The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 64: 27

    PubMed  CAS  Google Scholar 

  131. Wellens HJJ, Bar FW, Dassen WRM, Brugada P, Vanagt EJ, Farre J (1980) Effect of drugs in the Wolff-Parkinson-White syndrome. Am J Cardiol 46: 665

    PubMed  CAS  Google Scholar 

  132. Wellens HJJ, Bar FW, Vanagt EJ, Brugada P, Farre J (1981) The differentiation between ventricular tachycardia and supraventricular tachycardia with aberrant conduction: The value of the 12-lead-electrocardiogram. In: Wellens HJJ, Kulbertus HE (eds) What’s new in electrocardiography? Martinus Nijhoff Publishing, The Hague, pp 184

    Google Scholar 

  133. Wellens HJJ, Brugada P (1989) Treatment of cardiac arrhythmias: when, how and where? J Am Coll Cardiol 14: 1417

    PubMed  CAS  Google Scholar 

  134. Wilkinson PR, Rees JR, Storey GC, Holt DW (1984) Amiodarone prolonged elimination following cessation of chronic therapy. Am Heart J 107: 787

    PubMed  CAS  Google Scholar 

  135. Winkle RA (1978) Antiarrhythmic drug effect mimicked by spontaneous variability of ventricular ectopy. Circulation 57: 1116

    PubMed  CAS  Google Scholar 

  136. Zipes DP (1988) Proarrhythmic events. Am J Cardiol 61: 70A

    Google Scholar 

Download references

Authors
  1. D. Kalusche
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Herzchirurgie Salzburg, Müllner Hauptstraße 48, A-5020, Salzburg, Österreich

    Felix Unger

  2. Medizinische Klinik, Diakonissenkrankenhaus Mannheim, Akademisches Lehrkrankenhaus der Universität Heidelberg, Speyerer Straße 91-93, D-68163, Mannheim, Deutschland

    Hubert Mörl

  3. Fachpharmakologe DGPT, Am Huhlchen 5, D-55130, Mainz, Deutschland

    Hans Armin Dieterich

  4. School of Medicine, Dpts. of Medicine and Pharmacology, Georgetown University, Washington D.C., USA

    Hans Armin Dieterich

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kalusche, D. (1995). Medikamentöse Intervention bei Herzrhythmusstörungen. In: Unger, F., Mörl, H., Dieterich, H.A. (eds) Interventionen am Herzen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93558-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93558-9_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93559-6

  • Online ISBN: 978-3-642-93558-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation